Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICDs (implantable cardioverter defibrillators) coverage: Medicare extends comment period:

This article was originally published in Clinica

Executive Summary

Medicare's administrators have extended the public comment period on the health plan's coverage policy for implantable cardioverter defibrillators from June 23 to July 23, the Centers for Medicare & Medicaid Services (CMS) has announced. The additional time will give manufacturers and hospitals time to comment on three new questions recently posed by the agency: What is the evidence surrounding the necessity of threshold testing at the time of implantation? What is the evidence of benefits and risks of adding anti-tachycardia pacing to the function of an implantable defibrillator, including the risk of an additional lead? And finally, is there sufficient scientific justification for the development of an ICD patient registry to collect information to better identify predictors of ICD firing for ventricular fibrillation (as a proxy for sudden cardiac death)?

You may also be interested in...

Interview: Izana Tests GM-CSF Drug For Coronavirus

The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.

Building A Top-10 Global OTC Player – Q&A With HRA Pharma CEO David Wright

Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months. 

Bharat, UW-Madison, FluGen Pursue Intranasal COVID-19 Vaccine

Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts